GoBear is now part of Finder

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Gilead Sciences shares in Singapore | $62.79

Own Gilead Sciences share in just a few minutes.

Picture not described

Gilead Sciences, Inc is a drug manufacturers-general business based in the US. Gilead Sciences shares (GILD) are listed on the NASDAQ and all prices are listed in US Dollars. Gilead Sciences employs 13,600 staff and has a trailing 12-month revenue of around USD$25.6 billion.

How to buy shares in Gilead Sciences from Singapore

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Gilead Sciences Find the stock by name or ticker symbol: GILD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Gilead Sciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$62.79, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Gilead Sciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Gilead Sciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Compare online brokers to trade gold stocks, ETFs and CFDs

Name Product Number of Stocks CFDs Shares Available Markets
Saxo Markets
19,000+
Yes
Yes
AU, CN,CZ, DK, ES, FR, TW, HK, IT, HU, SA, NE, NO, PL, RU, SG, CH, UK, JP
CFD Service. Your capital is at risk.
Interactive Brokers
Access to global markets
Yes
Yes
Americas, Europe, Asia Pacific
CFD Service. Your capital is at risk.
Plus500
2,000+
Yes
No
US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK
CFD Service. Your capital is at risk.
BlackBull Markets
N/A
Yes
No
UK, HK, JP, MY, NZ, US
CFD Service. Your capital is at risk.
Libertex
50+
Yes
No
Worldwide with exception.
Except for: US/Australia/New Zealand/Belgium/British Virgin Islands/Guam/Lebanon/United States Minor/Outlying Islands/Northern Mariana Islands/Uganda/Philippines/Sri Lanka/Kuwait/South Africa/Azerbaijan/Canada/Armenia/Russia/Japan/Brasil.
CFD Service. Your capital is at risk.
Exness
N/A
Yes
No
CH, VN, TH, PH, SG, ID, IN, UAE, ZA, SA, EG, BR, CR, MX
CFD Service. Your capital is at risk.
IG
17,000+
Yes
No
DK, IE, NO, RU, DE, IT, AT, CH, ES, LU, PT, SE, FR, NL, RO, UK, US, AU, JP, SG, ZA, AE
CFD Service. Your capital is at risk.
loading

Compare up to 4 providers

How has coronavirus impacted Gilead Sciences's share price?

Since the stock market crash in March caused by coronavirus, Gilead Sciences's share price has had significant negative movement.

Its last market close was USD$62.79, which is 9.91% down on its pre-crash value of USD$69.7 and 2.04% down on the lowest point reached during the March crash when the shares fell as low as USD$64.07.

If you had bought USD$1,000 worth of Gilead Sciences shares at the start of February 2020, those shares would have been worth USD$1,094.23 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$946.25.

Gilead Sciences share price

Use our graph to track the performance of GILD stocks over time.

Gilead Sciences shares at a glance

Information last updated 2021-05-14.
Latest market closeUSD$62.79
52-week rangeUSD$55.9038 - USD$76.3778
50-day moving average USD$65.7797
200-day moving average USD$63.112
Wall St. target priceUSD$74.54
PE ratio 285.5417
Dividend yield USD$2.75 (3.99%)
Earnings per share (TTM) USD$0.24

Is it a good time to buy Gilead Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Gilead Sciences price performance over time

Historical closes compared with the last close of $62.79

1 week (2021-05-07) N/A
1 month (2021-04-16) -6.10%
3 months (2021-02-18) -3.74%
6 months (2020-11-18) 3.10%
1 year (2020-05-18) -16.01%
2 years (2019-05-17) -5.38%
3 years (2018-05-18) -7.69%
5 years (2016-05-18) -24.24%

Is Gilead Sciences under- or over-valued?

Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Gilead Sciences's P/E ratio

Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 286x. In other words, Gilead Sciences shares trade at around 286x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Gilead Sciences's PEG ratio

Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4957. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Gilead Sciences's EBITDA

Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$13.3 billion.

The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.

Gilead Sciences financials

Revenue TTM USD$25.6 billion
Operating margin TTM 45.69%
Gross profit TTM USD$21 billion
Return on assets TTM 11.48%
Return on equity TTM 1.33%
Profit margin 1.18%
Book value $15.113
Market capitalisation USD$85.9 billion

TTM: trailing 12 months

Shorting Gilead Sciences shares

There are currently 28.6 million Gilead Sciences shares held short by investors – that's known as Gilead Sciences's "short interest". This figure is 10.1% up from 26.0 million last month.

There are a few different ways that this level of interest in shorting Gilead Sciences shares can be evaluated.

Gilead Sciences's "short interest ratio" (SIR)

Gilead Sciences's "short interest ratio" (SIR) is the quantity of Gilead Sciences shares currently shorted divided by the average quantity of Gilead Sciences shares traded daily (recently around 6.9 million). Gilead Sciences's SIR currently stands at 4.15. In other words for every 100,000 Gilead Sciences shares traded daily on the market, roughly 4150 shares are currently held short.

However Gilead Sciences's short interest can also be evaluated against the total number of Gilead Sciences shares, or, against the total number of tradable Gilead Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gilead Sciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Gilead Sciences shares in existence, roughly 20 shares are currently held short) or 0.0228% of the tradable shares (for every 100,000 tradable Gilead Sciences shares, roughly 23 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Gilead Sciences.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask Finder

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site